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Background: For decades, Thailand has experienced high rates of illicit drug use and related harms. In response,
the Thai government has relied on drug law enforcement to address this problem. Despite these efforts, high rates
of drug use persist, and Thailand has been contending with an enduring epidemic of human immunodeficiency
virus (HIV) among people who inject drugs (IDU).
Methods: In response to concerns regarding drug-related harm in Thailand and a lack of research focused on the
experiences and needs of Thai IDU, the Mitsampan Community Research Project was launched in 2008. The project
involved administering surveys capturing a range of behavioral and other data to community-recruited IDU in
Bangkok in 2008 and 2009.
Results: In total, 468 IDU in Bangkok were enrolled in the project. Results revealed high rates of midazolam injection,
non-fatal overdose and incarceration. Syringe sharing remained widespread among this population, driven primarily
by problems with access to syringes and methamphetamine injection. As well, reports of police abuse were common
and found to be associated with high-risk behavior. Problems with access to evidence-based drug treatment and HIV
prevention programs were also documented. Although compulsory drug detention centers are widely used in
Thailand, data suggested that these centers have little impact on drug use behaviors among IDU in Bangkok.
Conclusions: The findings from this project highlight many ongoing health and social problems related to illicit
drug use and drug policies in Bangkok. They also suggest that the emphasis on criminal justice approaches has
resulted in human rights violations at the hands of police, and harms associated with compulsory drug detention
and incarceration. Collectively, the findings indicate the urgent need for the implementation of evidence-based
policies and programs in this setting.
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Thailand has experienced longstanding epidemics of
illicit drug use and human immunodeficiency virus
(HIV) among people who inject drugs (IDU). During the
1970s, Thailand became the world’s largest opium refi-
ning and distribution center, and accordingly, heroin use* Correspondence: uhritk@cfenet.ubc.ca
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reproduction in any medium, provided the orquickly became a major driver of drug-related harm in
this setting [1,2]. Since the late 1990s, there has been a
dramatic increase in the use of methamphetamine in
Thailand, which has become the most commonly used
illicit drug in the country today [3]. In response, the Thai
government has relied on criminal justice approaches in
an effort to eradicate illicit drugs. However, the national
household survey indicates that illicit drug use remains
widespread, with an estimated over 5% of the population
having used illicit drugs in 2007 [4]. The prevalence of
HIV among Thai IDU remains strikingly high, with ap-
proximately 30-40% of IDU living with HIV during thel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fers a range of HIV prevention, care and treatment ser-
vices for free (e.g., HIV testing and antiretroviral
therapy), past reports suggested that IDU faced many
barriers to access these services [6].
In response, IDU in Thailand have organized them-
selves and called for funding to institute evidence-based
harm reduction and treatment strategies for them. In
2003, a drug user-driven harm reduction initiative was
launched with funding from the Global Fund to Fight to
AIDS, Tuberculosis and Malaria (GFATM) [7]. Although
this civil society-driven movement led to the inclusion
of methadone treatment in the national health security
program in 2008 [5], needle and syringe programs
(NSPs), which is recommended by the World Health
Organization (WHO) and other United Nations (UN)
agencies as an essential HIV prevention service for IDU
[8], remain controversial: While public health authorities
have endorsed NSPs, legal authorities regard it as illegal
[9,10]. The legal uncertainty has created a challenging
environment for some civil society organizations that
were allowed to operate NSPs with funding from the
GFATM, while their service providers were routinely
arrested by police [6,11]. To date, the coverage of NSPs
remains as low as less than 1% among Thai IDU [12].
In 2002, Thailand enacted the Narcotic Addict Re-
habilitation Act B.E. 2545, which reclassified people who
use drugs as “patients” instead of “criminals.” Despite
this reclassification, in practice, Thailand continues to
support large-scale police crackdowns and the expansion
of compulsory drug detention centers (CDDCs) [13,14].
Most notably, a “war on drugs” policy in 2003 led to the
extrajudicial killings of over 2,800 people and sparked
criticism both domestically and internationally [15,16].
However, the intensive drug law enforcement-based ap-
proach continues to be endorsed by successive Thai go-
vernments [17,18], and the impact of this policy approach
on the health and behavior of IDU remains unevaluated.
As well, little is known about the coverage, quality, and
effectiveness of public health programs for IDU in this
setting.
In light of persistent concerns regarding drug policy in
Thailand, the Mitsampan Community Research Project,
an academic-community research partnership involving
people who use drugs in Bangkok, was launched in
2008. This report briefly describes the project and sum-
marizes the key peer-reviewed findings from the project.
Mitsampan Community Research Project and
research methods
The Mitsampan Community Research Project is a col-
laborative research effort involving the Mitsampan Harm
Reduction Center (MSHRC; Bangkok, Thailand), Thai AIDS
Treatment Action Group (TTAG; Bangkok, Thailand),Chulalongkorn University (Bangkok, Thailand), and the
Urban Health Research Initiative of the British Columbia
Centre for Excellence in HIV/AIDS/University of British
Columbia (Vancouver, Canada). The MSHRC is a drug
user-run drop-in center opened in 2004 with funding from
the GFATM. The center provides a range of programs and
harm reduction services (e.g., NSPs, health education, coun-
seling and assistance in accessing healthcare), and is also
active in advocating for the human rights of people who
use drugs. The overarching objectives of this research
were to investigate patterns of drug use, health services
use, interactions with the criminal justice system, and
health-related harms among IDU in Bangkok.
The specific methods employed in this research have
been described in detail elsewhere [19]. In brief, it em-
ploys a serial cross-sectional study design, and the data
used for this report were collected over two cycles of
surveying in August 2008 and June – July 2009. The
study participants were all active IDU residing in
Bangkok or in adjacent provinces and being ≥18 years
old when they enrolled in the study. Active IDU were
defined as individuals who had injected drugs at least
once in the six months prior to the interview. In 2008
and 2009, potential study participants were contacted
through peer outreach and word-of-mouth, and were in-
vited to the MSHRC to participate in the study. After
providing oral informed consent, participants completed
an interviewer-administered questionnaire covering a
range of topics including demographics, drug use pat-
terns, HIV risk behavior, health problems, access to
healthcare and harm reduction services, and experiences
with the criminal justice system. HIV seropositivity was
also determined through self-reporting. Since the study’s
focus on vulnerable populations and collecting data on
illegal activities raised ethical concerns, we employed
oral consent to protect the participant’s anonymity and
confidentiality. Additionally, the data collected did not
include any identifying information or permit identifica-
tion of specific individuals. The study was approved by
the research ethics boards of Chulalongkorn University
and the University of British Columbia.
This report summarizes the results of twelve peer-
reviewed studies conducted through the Mitsampan
Community Research Project. In keeping with the over-
arching research objectives, four studies were conducted
to investigate four different aspects of harms associated
with drug use [20-23]. Similarly, four studies examined
experiences of four different dimensions of drug law en-
forcement [24-27], and four studies focused on access to
various healthcare and harm reduction services among
IDU in Bangkok [28-31]. Because each study addressed a
different research question, they employed different par-
ticipant eligibility criteria, variables, sample sizes, and
statistical analyses. The analytical methods have been
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the studies, conventional regression methods (i.e., multi-
variable logistic regression) were used to address the
study objective.
Results: summary of findings
IDU recruitment
In total, 252 IDU participated in the study in August
2008, and 317 IDU participated in the study between
June and July 2009. Therefore, an accumulated total of
569 IDU were enrolled in the study over the two years.
Because 101 individuals participated in the study in both
years, the study reached a total of 468 unique IDU (252
individuals in 2008 and 216 individuals in 2009). Sample
characteristics are shown in Table 1. As shown, 157
(27.6%) were women, and the median age was 36 years
(interquartile range [IQR]: 32 – 46 years). The three
most commonly injected drugs by the study participants
during the previous six months were: heroin (91.3%),
midazolam (65.9%), and methamphetamine (57.5%) in
2008; and midazolam (80.4%), heroin (65.3%), and met-
hamphetamine (65.3%) in 2009. The prevalence of self-
reported HIV seropositivity was 17.4% over the two
years. Of note, 362 IDU (77.4%) newly accessed the
MSHRC as a result of their participation in the study,
and an increase in the attendance rate at the MSHRC
has been observed since the launch of the project [19].
The effective involvement of MSHRC members in the
study likely facilitated the observed high rates of IDU
recruitment [19].Table 1 Characteristics of a community-recruited sample of ID
Community Research Project in 2008 and 2009 (n = 569)
Characteristic Total n (%)
Female gender 157 (27.6%)
Age
< 35 years 243 (42.7%)
35-45 years 175 (30.8%)
≥ 46 years 151 (26.5%)




Self-reported HIV seropositivity 99 (17.4%)
Being on antiretroviral therapyb 54 (54.5%)c
IDUs: injection drug users.
a Denotes activities during the 6 months prior to the interview.
b Denotes activities at the time of interview.
c The number of HIV-infected individuals is used as a denominator.Drug-related harm
In order to better understand the health status of and
risks facing IDU in Bangkok, four studies were
conducted to examine the prevalence and correlates of
drug-related harm commonly experienced among the
study participants. Anecdotal reports suggested that an
increasing number of IDU in Bangkok were injecting
midazolam—a short-acting benzodiazepine that can be
acquired through private clinics. In 2008, over two thirds
(67.5%) of participants in our study reported a history of
midazolam injection, and 57.1% reported daily injection
of midazolam in the previous six months. Midazolam
injection was independently associated with poly-
substance use (adjusted odds ratio [AOR] = 5.86; 95%
CI: 2.96 – 11.60) and binge drug use (AOR = 2.25;
95% CI: 1.09 – 4.63), and was commonly used in com-
bination with both opiates and methamphetamine [20].
Our study involving 238 IDU in 2008 demonstrated
that 30.3% of participants reported syringe borrowing in
the past six months. Consistent with past research
[32,33], syringe borrowing was defined as injecting with
a syringe used by others. As shown in Figure 1, syringe
borrowing was independently associated with difficulty
accessing sterile syringes (adjusted odds ratio [AOR] =
2.46; 95% confidence interval [CI]: 1.08–5.60). Primary
reasons for experiencing difficulty accessing syringes in-
cluded being too far from syringe outlets, pharmacies
being closed, and being refused syringes at pharmacies
[21]. These findings suggest that poor access to sterile
syringes is driving the high rate of syringe borrowingUs in Bangkok, Thailand, participating in the Mitsampan
Study enrolment
2008 2009
252 (44.3%) 317 (55.7%)
n (column%) n (column%)
66 (26.2%) 91 (28.7%)
111 (44.0%) 132 (41.6%)
74 (29.4%) 101 (31.9%)
67 (26.6%) 84 (26.5%)
230 (91.3%) 207 (65.3%)
145 (57.5%) 207 (65.3%)
166 (65.9%) 255 (80.4%)
29 (11.5%) 70 (22.1%)
21 (72.4%)c 33 (47.1%)c
Figure 1 Multivariate logistic regression analysis of factors associated with syringe borrowing among Thai IDU (n = 238).
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roborate this interpretation [34,35].
Methamphetamine injection appeared to be increasing
among IDU in Bangkok, raising concerns about the as-
sociated impacts on HIV risk behavior among this popu-
lation. Among 311 study participants in 2009, 36.7%
reported having injected methamphetamine pills, locally
referred to as “yaba,” twice or more per week in the pre-
vious six months. The prevalence of methamphetamine
injection observed in this study was much higher than
previously reported rates using data collected during
1999 and 2004 [36,37]. In multivariate logistic regression
analyses, after adjustment for potential social, demo-
graphic and behavioral confounders, syringe sharing (i.e.,
borrowing or lending used syringes from or to others)
in the past six months remained independently associ-
ated with injecting methamphetamine more than once
per week (AOR = 2.86; 95% CI: 1.59–5.15) [22].
Although drug-related overdose is a leading cause of
death among people who use drugs globally [38-40], the
overdose experiences of Thai IDU have not been investi-
gated. Our study conducted in 2008 found that 29.8% of
participants had a history of overdose, and reporting a
history of overdose was independently associated with a
history of incarceration (AOR = 3.83; 95% CI: 1.52 – 9.65).Table 2 Multivariate logistic regression analysis of factors ass
Thai IDU (n = 252)
Variable Adjusted Odds R
Ever used drugs in combination
(yes vs. no) 1.78
Ever had drugs planted by police
(yes vs. no) 1.81
Median daily expenses for purchasing drugs
(≥ 300 THB vs. < 300 THB) 1.86
Reproduced from Csete et al. [25].The majority of participants (67.9%) had also responded
at the scene of an overdose. While many reported re-
sponses with resuscitative potential, almost half reported
engaging in responses with low life-saving potential,
such as injecting the individual with salt water [23].
Experiences with drug law enforcement
Given the ongoing emphasis on drug law enforcement
in Thailand, we conducted a series of analyses to exa-
mine experiences with drug law enforcement among 252
IDU recruited in 2008. The first study exploring incar-
ceration experiences demonstrated high rates of HIV
risk behavior among IDU who had been in prison. The
majority of participants (78.2%) reported a history of
incarceration, and approximately 30% reported using
drugs while in prison; 81.4% of these individuals also
shared used syringes while incarcerated. A history of im-
prisonment was independently associated with a history
of syringe sharing (AOR = 2.20; 95% CI: 1.12 - 4.32) [24].
Our examination of the prevalence and correlates of
experiences with CDDCs revealed that 31.7% of partici-
pants had been in a CDDC at some point. As shown in
Table 2, the exposure to CDDCs was independently
associated with experiencing police abuse (i.e., having
illicit drugs planted on oneself by police) (AOR = 1.81;ociated with compulsory drug detention exposure among
atio (AOR) 95% Confidence Interval (CI) p-value
(0.94 – 3.36) 0.078
(1.04 – 3.15) 0.035
(1.07 – 3.22) 0.028
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jection drug use did not differ between those who were
and were not exposed to CDDCs (p > 0.14) [25]. These
findings suggest that CDDCs are associated with police
abuse and appear not to be helping to reduce drug use
among IDU in Bangkok.
Previous studies have shown that intensive drug mar-
ket policing can produce harmful impacts on public
health [41]. In two separate studies, encounters with po-
lice were operationalized into two variables: (1) experi-
ences with evidence planting by police (in the form of
police placing illicit drugs on an individual) as an indica-
tor of direct encounters with police; and (2) perceiving
an increase in police presence where people obtained or
used drugs in the previous six months as an indicator of
indirect encounters with police. The first study revealed
a high rate of police abuse against IDU: 48.4% of partici-
pants reported having illicit drugs planted on them by
police. In multivariate analyses, this form of police mis-
conduct was strongly associated with a history of over-
dose (AOR = 2.56; 95% CI: 1.40 – 4.66), syringe lending
(AOR = 2.08; 95% CI: 1.19 – 3.66) and having been in a
CDDC (AOR = 1.88; 95% CI: 1.05 – 3.36). Moreover,
among those who reported having drugs planted on
them by police, almost half (48.3%) paid police a bribe
(median = 5,000 Thai Baht or approximately $140 USD)
in order to avoid arrest [26].
Among the same sample, 54.4% reported observing an
increase in police presence where they obtained or used
drugs in the previous six months. However, levels of
drug use did not vary among those who did and did notFigure 2 Multivariate logistic regression analysis of factors associated
among a community-recruited sample of people who inject drugs inreport observing an increase in police presence [27].
Despite the continued use of police crackdowns, the
findings suggest that increasing police presence in drug
markets appears to have had little effect in reducing
drug use among IDU in Bangkok.
Access to health care and harm reduction services
Four studies have been conducted to examine access to
essential health and harm reduction services among IDU
in Bangkok. The first study sought to investigate access
to methadone treatment, one of the core interventions
for HIV prevention and care for IDU [8]. While metha-
done treatment has been available in Bangkok for de-
cades, concerns have been raised regarding inadequate
daily dosing and the provision of methadone as a short
detoxification program [42]. To conduct an external as-
sessment of methadone treatment programs in Bangkok,
273 IDU who had a history of heroin or other opiate use
were recruited in 2009. In total, 52.4% opiate users had
accessed methadone treatment in the previous six
months, but almost all (98.6%) of them relapsed into ac-
tive drug use while on treatment. As shown in Figure 2,
injecting midazolam twice or more per week was inde-
pendently associated with being enrolled in methadone
treatment (AOR = 1.85; 95% CI: 1.04 – 3.29). High rates
of ongoing drug use among methadone patients is likely
indicative of the suboptimal system of methadone
provision in Bangkok, consistent with previous reports
[42]. Moreover, 72.7% reported having stopped metha-
done treatment, and the most common reason for stop-
ping methadone was incarceration [28].with accessing methadone treatment in the previous 6 months
Bangkok, Thailand (n = 273).
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tors associated with HIV testing behavior and explored
the willingness to access rapid HIV testing at the
MSHRC among HIV-negative IDU or IDU of unknown
HIV serostatus. Although 76.2% of the study sample re-
ceived HIV testing in the previous six months, 56.9% of
those who had not been tested in the previous six
months reported engaging in HIV risk behavior in the
previous six months. Also, it was unclear whether the
high rate of testing observed in the study was partially a
reflection of the existence of the tenofovir trial (a pre-
exposure prophylaxis trial conducted out of Bangkok
Metropolitan Administration methadone clinics) [43],
as enrolment in the trial was strongly associated with
receiving HIV testing (odds ratio = 44.81; 95% CI:
13.44 – 149.45). In total, 74.2% of participants expressed
willingness to receive rapid HIV testing at the MSHRC
if it were made available [29].
The third study examined access to testing for hepa-
titis C virus (HCV) among IDU who were living with
HIV. Although HIV and HCV co-infection is highly
prevalent among Thai IDU [44], and WHO recommends
that all people living with HIV be screened for HCV
[45], only half (52.2%) of the HIV-infected IDU who en-
rolled in the study had ever been tested for HCV. This
appeared to be related to a lack of awareness of HCV, as
primary reasons given for not getting tested for HCV in-
cluded “never heard of HCV” (65.6%) and “not aware of
HCV risks” (37.5%). Further, rates of HCV risk behavior
(i.e., syringe sharing) were high (38.2%) among HIV-
positive IDU who did not know their HCV status [30].
The deficit in HCV case finding uncovered in this
study is significant, given the high rates of HCV risk
behavior observed among the study sample and the in-
dependent contribution of HCV to morbidity and mor-
tality among HIV-infected IDU [46].
Lastly, an evaluation of the MSHRC was conducted
by examining factors associated with access to the
MSHRC. In 2008, 29.3% of participants surveyed had
accessed the MSHRC, and these individuals were four
times more likely to have had difficulty accessing ste-
rile syringes than those who had not previously
accessed the MSHRC (AOR = 4.05; 95% CI: 1.67 –
9.80). Forms of support most commonly accessed at
the MSHRC included sterile syringes (100%), food and
a place to rest (83.8%), and information about HIV
(75.7%) and safer injecting (66.2%) [31]. Consistent
with a large body of research indicating the benefits of
peer-based approaches in providing public health edu-
cation and services to IDU [47-50], the results of this
study demonstrated that the peer-run MSHRC is helping
to expand harm reduction programming in Bangkok by
reaching a sub-population of IDU at heightened risk of
HIV infection.Discussion
The results of the Mitsampan Community Research Pro-
ject reveal that IDU in Bangkok continue to engage in
high rates of HIV risk behavior (i.e., syringe sharing) and
suffer from high rates of drug-related harm, including
overdose. The findings also indicate a lack of appropriate
healthcare service provision and problems with subopti-
mal service delivery among this population, as low rates
of sterile syringe access, HCV testing and awareness,
and poor outcomes from methadone treatment persist.
A number of social and structural factors appear to be
driving these problems, including the limited availabi-
lity of evidence-based interventions targeting IDU, an
overreliance on drug law enforcement and incarce-
ration, and a failure to adhere to international guide-
lines on HIV prevention and care, and drug treatment
for IDU. Although Thailand has continued to rely on
intensive drug law enforcement, the evidence derived
from this study suggest that this approach is failing to
produce reductions in drug use, and is associated with
human rights violations and the perpetuation of a sys-
tem of compulsory drug detention that appears to have
little impact on the drug use behaviors of IDU in
Bangkok. On the other hand, a promising means to re-
duce drug-related harm among this population was
identified at the drug user-run harm reduction center
where IDU experiencing difficulty in accessing sterile
syringes obtain sterile syringes and other supports.
Many of our findings are congruent with previous
studies identifying various pathways through which in-
tensified drug law enforcement produces harmful im-
pacts on the health of IDU and public health [41,51-54].
For example, in previous studies from other countries,
increasing policing in drug markets has been shown to
have had no effect in reducing injection drug use [54]
but instead have resulted in shifts in local drug use pat-
terns and greater harm [51,55]. Our research also de-
monstrated that perceived increases in police presence
in drug markets did not seem to reduce injecting beha-
vior among IDU in Bangkok [27]. As well, data from this
project suggested that midazolam and methampheta-
mine injection is increasing despite ongoing intensive
police crackdowns, and injection of these substances was
shown to be associated with risk factors of HIV infection
and overdose [20,22]. In particular, the finding that the
observed prevalence of methamphetamine injection
appeared to be higher than the previously reported rates
may reflect the concurrent growth of the methampheta-
mine market suggested in the government’s reports [3],
although this explanation warrants a further examin-
ation. Further, the observed high rates of police abuse
and the strong association with risk taking among IDU
in this setting [26] is consistent with previous research
indicating that aggressive policing practices not only
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ways to more distal forms of drug-related harm
[41,52,56,57].
Our findings also point to the urgent need for the
implementation of harm reduction measures within
prisons. According to the latest official report, 56.4% of
all incarceration events in Thailand are attributable to
drug-related charges [58]. Consistent with previous stu-
dies [59-61], our study demonstrated alarmingly high
rates of HIV risk behavior among IDU in Bangkok who
reported a history of incarceration [24]. Moreover, incar-
ceration was also associated with overdose [23] and was
reported to be the most common reason for the discon-
tinuation of methadone treatment [28]. The independent
association between overdose and incarceration is con-
sistent with evidence from Western settings indicating
that incarceration exacerbates the risk of heroin over-
dose upon release from prisons as a result of reduced
tolerance [62]. These findings suggest that incarceration
is contributing to the production of a variety of drug-
related harms in this setting. Given the ongoing high
rates of incarceration of Thai IDU, our findings reinforce
the recommendations by WHO and other UN agencies
to implement essential harm reduction programs within
prisons, including NSPs [53].
The findings of this research also highlight the need to
scale up HIV prevention, care and treatment services
targeted for IDU in Bangkok. The HIV prevalence
among our study sample (17.4%) was high and similar to
the 2010 Integrated Biological and Behavioral Surveys
data showing that the HIV prevalence was 21.3% (CI:
15.2-26.5) among a sample of 412 IDU in Bangkok [63].
The observed rate of syringe borrowing (30%) [21] was
higher than the rates of syringe sharing among IDU in
Bangkok reported by two other studies in 2003–2004
(17%) [37] and 2009 (14%) [64], although the potential
differences in sample characteristics make the compari-
son difficult. The finding that frequent methampheta-
mine injection had an independent relationship with
syringe sharing [22] builds on previous studies showing
heightened risk of HIV seroconversion among metham-
phetamine injectors [36,61] and calls for the scale-up of
NSPs for this sub-population of IDU. Although the Thai
government supports some harm reduction programs,
the illegality of NSPs is still debated [10]. Given the
demonstrated strengths of the MSHRC in reaching a
sub-population of IDU at heightened risk of HIV infec-
tion due to difficulty accessing sterile syringes [31] and
the fact that the MSHRC, like many other drop-in cen-
ters implementing NSPs that are operated by civil soci-
ety organizations, relies on the GFATM grant [11], such
peer-run interventions should be supported and scaled
up by the government. Also, given the substantial level
of willingness to access rapid HIV testing at the MSHRCamong HIV-negative IDU or IDU of unknown HIV
serostatus [29], it may worth exploring the expansion of
peer-led harm reduction interventions in this setting,
such as the provision of HIV testing and counseling
by peers.
The work described in this report has limitations, and
the limitations of each individual study are described in
detail in the published versions of the studies. First, as in
any research that is based on surveying methods, our re-
search cannot prove causal relationships. Second, as the
study sample was not randomly recruited, our findings
may not be generalizable to the IDU populations in
Bangkok or other parts of Thailand. Third, the self-
reported data may be affected by response biases, in-
cluding socially desirable reporting and recall bias.
Therefore, we may have over- or underestimated the
true prevalence of drug use or HIV risk behaviors
among IDU in Bangkok. However, we also note that this
type of data has been commonly utilized in other studies
examining drug use patterns and found to be valid
[65,66]. Finally, building on the present research fin-
dings, future research should further examine observed
associations between various health and social prob-
lems and injection drug use, including the relationship
between midazolam injection and dosages of methadone.
Conclusions
The findings from this research project highlight many
ongoing health and social problems related to illicit drug
use among IDU in Bangkok. They indicate a lack of
appropriate healthcare and harm reduction service
provision to this population, problems which are likely
contributing to ongoing HIV risk-taking and other drug-
related harms within this population. These findings also
suggest that the emphasis on criminal justice approaches
has resulted in human rights violations at the hands of
police, and harms associated with compulsory drug de-
tention and incarceration. Collectively, the findings indi-
cate the need for urgent government endorsement,
funding and independent evaluation of a comprehensive
set of IDU-specific harm reduction and addiction treat-
ment programs in Bangkok.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KH drafted the manuscript and incorporated all suggestions from co-authors.
All authors made significant contributions to the conception of the analyses,
interpretation of the data, and drafting of the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
We would particularly like to thank the staff and volunteers at the
Mitsampan Harm Reduction Center for their support. We also thank
Dr. Niyada Kiatying-Angsulee, Director of Social Research Institute,
Chulalongkorn University, for her assistance with developing this project.
We gratefully acknowledge a number of graduate students and staff for their
Hayashi et al. Harm Reduction Journal 2013, 10:21 Page 8 of 9
http://www.harmreductionjournal.com/content/10/1/21assistance with data collection and management: Prempreeda Pramoj Na
Ayutthaya, Amnat Chamchern, Wiwat Chotichatmala, Tricia Collingham, Eric
Fu, Deborah Graham, Donlachai Hawangchu, Caitlin Johnston, Prapatsara
Kaewkoon, Daniel Miles Kane, Calvin Lai, Puripakorn Pakdirat, Cristy Power,
Jiezhi Qi, Jirasak Sripramong, Vipawan Suwannawong, Kamon Uppakaew,
Peter Vann, Tanyaporn Wansom, and Ruth Zhang. We also thank Joanne
Csete, M-J Milloy, Julio Montaner, and Dan Werb for their invaluable
contribution to the development of the manuscripts. Particular thanks go to
the participants in the project who were courageous enough to share their
experiences with us. The project was originally funded by the Michael Smith
Foundation for Health Research. Its knowledge translation activities were
supported by the Public Health Program and Global Drug Policy Program of
the Open Society Foundations. TK is supported by the Michael Smith
Foundation for Health Research. KH is supported by the University of British
Columbia Doctoral Fellowship.
Author details
1Urban Health Research Initiative, British Columbia Centre for Excellence in
HIV/AIDS, St. Paul’s Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6,
Canada. 2Interdisciplinary Studies Graduate Program, University of British
Columbia, Green College, Green Commons, Room 153A, 6201 Cecil Green
Park Rd, Vancouver, BC V6T 1Z1, Canada. 3Faculty of Medicine, University of
British Columbia, 317-2194 Health Sciences Mall, Vancouver, BC V6T 1Z3,
Canada. 4Mitsampan Harm Reduction Center / Thai AIDS Treatment Action
Group, 18/89 Vipawadee Rd., soi 40 Chatuchak, Bangkok 10900, Thailand.
Received: 9 July 2012 Accepted: 24 September 2013
Published: 7 October 2013
References
1. Reid G, Costigan G: Revisiting the hidden epidemic: a situation assessment of
drug use in Asia in the context of HIV/AIDS. Fairfield: The Center for Harm
Reduction, The Burnet Institute; 2002.
2. McCoy AW, Read CB, Adams LP II: The politics of heroin in Southeast Asia.
New York: Harper Colophon Books; 1972.
3. Global SMART Programme: Patterns and trends of amphetamine-type
stimulants and other drugs: Asia and the Pacific. Vienna: United Nations
Office on Drugs and Crime (UNODC); 2011.
4. Assanangkornchai S, Aramrattana A, Perngparn U, Kanato M, Kanika N, Na
Ayudhya AS: Current situation of substance-related problems in Thailand.
J Psych Associ Thai 2008, 53(Supplement 1):24S–36S.
5. National AIDS Prevention and Alleviation Committee: UNGASS Country
Progress Report Thailand: Reporting Period: January 2008 - December 2009.
Bangkok; 2010. http://data.unaids.org/pub/Report/2010/thailand_2010_
country_progress_report_en.pdf.
6. Human Rights Watch, Thai AIDS Treatment Action Group: Deadly Denial:
Barriers to HIV/AIDS Treatment for People who use Drugs in Thailand. Vol.19.
New York: Human Rights Watch; 2007.
7. Kerr T, Kaplan K, Suwannawong P, Jurgens R, Wood E: The global fund to
fight AIDS, tuberculosis and malaria: funding for unpopular public-health
programmes. Lancet 2004, 364(9428):11–12.
8. World Health Organization (WHO), United Nations Office on Drugs and
Crime (UNODC), The Joint United Nations Programme on HIV/AIDS
(UNAIDS): WHO, UNODC, UNAIDS Technical Guide for Countries to set Targets
for Universal Access to HIV Prevention, Treatment and Care for Injecting Drug
Users. Geneva: World Health Organization; 2009.
9. Woon laew! Sanub Sanun chai kem upakorn cheed tee sa-ad pongkan
karn tid chuea HIV so pid kod mai [Promotion of clean syringes and
paraphernalia for HIV prevention found breaching the law]. Matichon
Online 2011. http://www.matichon.co.th/news_detail.php?newsid=
1313497910&grpid=03&catid=&subcatid.
10. Thailand AIDS Response Progress Report 2012: Reporting Period: 2010–2011;
2012. http://www.unaids.org/en/dataanalysis/knowyourresponse/
countryprogressreports/2012countries/ce_TH_Narrative_Report[1].pdf.
11. Harm Reduction International: In The global state of harm reduction 2012:
towards an integrated response. Edited by Stoicescu C. London: Harm
Reduction International; 2012.
12. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, Myers
B, Ambekar A, Strathdee SA: HIV prevention, treatment, and care services
for people who inject drugs: a systematic review of global, regional, and
national coverage. Lancet 2010, 375(9719):1014–1028.13. Pearshouse R: Compulsory Drug Treatment in Thailand: Observations on
the Narcotic Addict Rehabilitation Act B.E. 2545 (2002). Toronto: Canadian
HIV/AIDS Legal Network; 2009.
14. Thomson N: Detention as Treatment: Detention of Methamphetamine Users in
Cambodia, Laos, and Thailand. New York: International Harm Reduction
Development Program, Open Society Institute; 2010.
15. Human Rights Watch: Not Enough Graves: the war on Drugs, HIV/AIDS, and
Violations of Human Rights. Vol. 16. New York: Human Rights Watch; 2004.
16. Harm Reduction International, Human Rights Watch: Thailand’s ‘war On
drugs’; 2008. http://www.hrw.org/news/2008/03/12/thailand-s-war-drugs.
17. Thailand Office of the Narcotics Control Board: Roadmap of Drug
Surveillance and Establishment of Sustainable Victory Over Drugs 2006–2008.
Bangkok; 2006. http://en.oncb.go.th/document/Roadmap06-08.pdf.
18. Thailand Office of the Narcotics Control Board: National Narcotics Control
Policy on Five Fences Strategy: 2009–2010. Bangkok; 2009. http://en.oncb.go.
th/document/e1-info-5Fence.html.
19. Hayashi K, Fairbairn N, Suwannawong P, Kaplan K, Wood E, Kerr T:
Collective empowerment while creating knowledge: a description of
a community-based participatory research project with drug users in
Bangkok, Thailand. Subst Use Misuse 2012, 47(5):502–510.
20. Kerr T, Kiatying-Angsule N, Fairbairn N, Hayashi K, Suwannawong P, Kaplan
K, Zhang R, Wood E: High rates of midazolam injection among drug users
in Bangkok, Thailand. Harm Reduction Journal 2010, 7(1):7.
21. Kerr T, Fairbairn N, Hayashi K, Suwannawong P, Kaplan K, Zhang R, Wood E:
Difficulty accessing syringes and syringe borrowing among injection
drug users in Bangkok, Thailand. Drug Alcohol Rev 2010, 29(2):157–161.
22. Hayashi K, Wood E, Suwannawong P, Kaplan K, Qi J, Kerr T:
Methamphetamine injection and syringe sharing among a community-
recruited sample of injection drug users in Bangkok, Thailand. Drug
Alcohol Depend 2011, 115(1–2):145–149.
23. Milloy MJ, Fairbairn N, Hayashi K, Suwannawong P, Kaplan K, Wood E, Kerr T:
Overdose experiences among injection drug users in Bangkok, Thailand.
Harm Reduction J 2010, 7:9.
24. Hayashi K, Milloy MJ, Fairbairn N, Kaplan K, Lai C, Wood E, Kerr T:
Incarceration experiences among a community-recruited sample of
injection drug users in Bangkok, Thailand. BMC Public Health 2009,
9(1):492.
25. Csete J, Kaplan K, Hayashi K, Fairbairn N, Suwannawong P, Zhang R, Wood
E, Kerr T: Compulsory drug detention center experiences among a
community-based sample of injection drug users in Bangkok, Thailand.
BMC Int Health Human Rights 2011, 11(1):12.
26. Fairbairn N, Kaplan K, Hayashi K, Suwannawong P, Lai C, Wood E, Kerr T:
Reports of evidence planting by police among a community-based
sample of injection drug users in Bangkok, Thailand. BMC Int Health
Human Rights 2009, 9:24.
27. Werb D, Hayashi K, Fairbairn N, Kaplan K, Suwannawong P, Lai C, Kerr T:
Drug use patterns among Thai illicit drug injectors amidst increased
police presence. Subst Abuse Treat Prev Policy 2009, 4:16.
28. Fairbairn N, Hayashi K, Kaplan K, Suwannawong P, Qi J, Wood E, Kerr T:
Factors associated with methadone treatment among injection drug
users in Bangkok, Thailand. J Subst Abuse Treat 2012, 43(1):108–113.
29. Ti L, Hayashi K, Kaplan K, Suwannawong P, Fu E, Wood E, Kerr T: HIV testing
and willingness to get HIV testing at a peer-run drop-in centre for
people who inject drugs in Bangkok, Thailand. BMC Public Health 2012,
12(1):189.
30. Hayashi K, Montaner J, Kaplan K, Suwannawong P, Wood E, Qi J, Kerr T:
Low uptake of hepatitis C testing and high prevalence of risk behavior
among HIV-positive injection drug users in Bangkok, Thailand. J Acquir
Immune Defic Syndr 2011, 56(5):e133–e135.
31. Kerr T, Hayashi K, Fairbairn N, Kaplan K, Suwannawong P, Zhang R, Wood E:
Expanding the reach of harm reduction in Thailand: experiences with a
drug user-run drop-in centre. Int J Drug Policy 2010, 21(3):255–258.
32. Marshall BD, Wood E, Li K, Kerr T: Elevated syringe borrowing among men
who have sex with men: a prospective study. J Acquir Immune Defic Syndr
2007, 46(2):248–252.
33. Pollini RA, Brouwer KC, Lozada RM, Ramos R, Cruz MF, Magis-Rodriguez C,
Case P, Burris S, Pu M, Frost SD, et al: Syringe possession arrests are
associated with receptive syringe sharing in two Mexico-US border
cities. Addiction 2008, 103(1):101–108.
34. Perngmark P, Celentano DD, Kawichai S: Needle sharing among southern
Thai drug injectors. Addiction 2003, 98(8):1153–1161.
Hayashi et al. Harm Reduction Journal 2013, 10:21 Page 9 of 9
http://www.harmreductionjournal.com/content/10/1/2135. Perngmark P, Vanichseni S, Celentano DD: The Thai HIV/AIDS epidemic at
15 years: sustained needle sharing among southern Thai drug injectors.
Drug Alcohol Depend 2008, 92(1–3):183–190.
36. Martin M, Vanichseni S, Suntharasamai P, Mock PA, Van Griensven F,
Pitisuttithum P, Tappero JW, Chiamwongpaet S, Sangkum U, Kitayaporn D,
et al: Drug use and the risk of HIV infection amongst injection drug users
participating in an HIV vaccine trial in Bangkok, 1999–2003. Int J Drug
Policy 2010, 21(4):296–301.
37. Wattana W, Van Griensven F, Rhucharoenpornpanich O, Manopaiboon C,
Thienkrua W, Bannatham R, Fox K, Mock PA, Tappero JW, Levine WC:
Respondent-driven sampling to assess characteristics and estimate the
number of injection drug users in Bangkok, Thailand. Drug Alcohol
Depend 2007, 90(2–3):228–233.
38. Hulse GK, English DR, Milne E, Holman CD: The quantification of mortality
resulting from the regular use of illicit opiates. Addiction 1999,
94(2):221–229.
39. Stoove MA, Dietze PM, Aitken CK, Jolley D: Mortality among injecting drug
users in Melbourne: a 16-year follow-up of the Victorian Injecting Cohort
Study (VICS). Drug Alcohol Depend 2008, 96(3):281–285.
40. Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, McLaren
J: Mortality among regular or dependent users of heroin and other
opioids: a systematic review and meta-analysis of cohort studies.
Addiction 2011, 106(1):32–51.
41. Kerr T, Small W, Wood E: The public health and social impacts of drug
market enforcement: a review of the evidence. Int J Drug Policy 2005,
16(4):210–220.
42. Tyndall M: Harm reduction policies and interventions for injection drug users in
Thailand. Bangkok: World Bank; 2011.
43. Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Chuachoowong R,
Mock PA, Leethochawalit M, Chiamwongpaet S, Kittimunkong S, Van
Griensven F, et al: Enrollment characteristics and risk behaviors of
injection drug users participating in the Bangkok Tenofovir Study,
Thailand. PLoS One 2011, 6(9):e25127.
44. Walsh N, Verster A, Doupe A, Vitoria M, Lo Y-R, Wiersma S: 3.1. The silent
epidemic: responding to viral hepatitis among people who inject drugs.
In Global State of Harm Reduction 2010: Key Issues for Broadening the
Response. Edited by Cook C. London: International Harm Reduction
Association; 2010.
45. World Health Organization Regional Office for Europe (WHO-EURO):
6. Management of hepatitis C and HIV coinfection. In HIV/AIDS Treatment
and Care: Clinical Protocols for the WHO European Region. Edited by Eramova
I, Matic S, Munz M. Copenhagen: WHO-EURO; 2007.
46. Sulkowski MS, Thomas DL: Hepatitis C in the HIV-infected person. Ann
Intern Med 2003, 138(3):197–207.
47. Broadhead RS, Heckathorn DD, Weakliem DL, Anthony DL, Madray H, Mills
RJ, Hughes J: Harnessing peer networks as an instrument for AIDS
prevention: results from a peer-driven intervention. Public Health Rep
1998, 113(Suppl 1):42–57.
48. Grund JP, Blanken P, Adriaans NF, Kaplan CD, Barendregt C, Meeuwsen M:
Reaching the unreached: targeting hidden IDU populations with clean
needles via known user groups. J Psychoactive Drugs 1992, 24(1):41–47.
49. Latkin CA: Outreach in natural settings: the use of peer leaders for HIV
prevention among injecting drug users’ networks. Public Health Rep 1998,
113(Suppl 1):151–159.
50. Needle RH, Burrows D, Friedman SR, Dorabjee J, TouzÈ G, Badrieva L, Grund
J-PC, Kumar MS, Nigro L, Manning G, Latkin C: Effectiveness of community-
based outreach in preventing HIV/AIDS among injecting drug users.
I J Drug Policy 2005, 16(Supplement 1):45–57.
51. Maher L, Dixon D: Policing and public health: law enforcement and harm
minimization in a street-level drug market. Br J Criminol 1999,
39(4):488–512.
52. Burris S, Blankenship KM, Donoghoe M, Sherman S, Vernick JS, Case P,
Lazzarini Z, Koester S: Addressing the “risk environment” for injection
drug users: the mysterious case of the missing cop. Milbank Q 2004,
82(1):125–156.
53. Jurgens R: Effectiveness of Interventions to Address HIV in Prisons. Geneva:
World Health Organization (WHO), United Nations Office on Drugs and
Crime (UNODC), and Joint United Nations Programme on HIV/AIDS
(UNAIDS); 2007.
54. Friedman SR, Cooper HL, Tempalski B, Keem M, Friedman R, Flom PL, Des
Jarlais DC: Relationships of deterrence and law enforcement to drug-related harms among drug injectors in US metropolitan areas. AIDS 2006,
20(1):93–99.
55. Maher L, Li J, Jalaludin B, Wand H, Jayasuriya R, Dixon D, Kaldor JM:
Impact of a reduction in heroin availability on patterns of drug use, risk
behaviour and incidence of hepatitis C virus infection in injecting drug
users in New South Wales, Australia. Drug Alcohol Depend 2007,
89(2–3):244–250.
56. Small W, Kerr T, Charette J, Schechter MT, Spittal PM: Impacts of intensified
police activity on injection drug users: evidence from an ethnographic
investigation. Int J Drug Policy 2006, 17(2):85–95.
57. Sarang A, Rhodes T, Sheon N, Page K: Policing drug users in Russia: risk,
fear, and structural violence. Subst Use Misuse 2010, 45(6):813–864.
58. Department of Corrections, Ministry of Justice, Thailand: Number of
Convicted Prisoners by Type of Offences. http://www.correct.go.th/eng/
number_by_type_of_offences.html.
59. Beyrer C, Jittiwutikarn J, Teokul W, Razak MH, Suriyanon V, Srirak N,
Vongchuk T, Tovanabutra S, Sripaipan T, Celentano DD: Drug use,
increasing incarceration rates, and prison-associated HIV risks in
Thailand. AIDS Behav 2003, 7(2):153–161.
60. Choopanya K, Des Jarlais DC, Vanichseni S, Kitayaporn D, Mock PA, Raktham
S, Hireanras K, Heyward WL, Sujarita S, Mastro TD: Incarceration and risk for
HIV infection among injection drug users in Bangkok. J Acquir Immune
Defic Syndr 2002, 29(1):86–94.
61. Buavirat A, Page-Shafer K, Van Griensven GJP, Mandel JS, Evans J,
Chuaratanaphong J, Chiamwongpat S, Sacks R, Moss A: Risk of prevalent
HIV infection associated with incarceration among injecting drug users
in Bangkok, Thailand: case–control study. Br Med J 2003, 326(7384):308.
62. Darke S, Hall W: Heroin overdose: research and evidence-based
intervention. J Urban Health 2003, 80(2):189–200.
63. Punsuwan N, Namwat C, Tanpradech S, Pratheepkaew N, Yodreaun K,
Jarupan S: Correlates of HIV infection among injection drug users in
Bangkok Metropolitan Regions, Chiangmai and Songkhla, Thailand
[abstract]. In The 10th International Congress on AIDS in Asia and the Pacific:
26–30 Augusut 2011. Busan, Korea: SuPA042:209.
64. Barrett ME, Perngparn U: Rapid Assessment and Response: Preparation for the
Scale-up of Comprehensive Harm Reduction Services in Thailand: Bangkok
Province. Bangkok: Asian Harm Reduction Network & Public Health Sciences
College, Chulalongkorn University; 2010.
65. Weatherby NL, Needle R, Cesari H, Booth R, McCoy CB, Watters JK, Williams
M, Chitwood DD: Validity of self-reported drug use among injection drug
users and crack cocaine users recruited through street outreach. Eval
Program Plann 1994, 17(4):347–355.
66. Darke S: Self-report among injecting drug users: a review. Drug Alcohol
Depend 1998, 51(3):253–263. discussion 267–258.
doi:10.1186/1477-7517-10-21
Cite this article as: Hayashi et al.: Drug-related harm among people who
inject drugs in Thailand: summary findings from the Mitsampan
Community Research Project. Harm Reduction Journal 2013 10:21.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
